HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

Media coverage

• Title	Phase 1 HB 200 Data Show Unprecedented T Cell Response, Favorable Tolerability, and Preliminary Efficacy as Monotherapy for Advanced HPV16+ Cancers
  Media name/outlet	Market News Publishing
  Country/Territory	United States
  Date	8/06/21
  Persons	Dmitriy Zamarin

• Title	-HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	8/06/21
  Persons	Dmitriy Zamarin

• Title	HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
  Media name/outlet	India Pharma News
  Country/Territory	India
  Date	7/06/21
  Persons	Dmitriy Zamarin